Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Drug Des Devel Ther ; 18: 3255-3266, 2024.
Article de Anglais | MEDLINE | ID: mdl-39081704

RÉSUMÉ

Fibrosis leads to organ failure and death, which is the final stage of many chronic diseases. Triptolide (TPL) is a terpenoid extracted from the traditional Chinese medicine Tripterygium wilfordii Hook. F (TwHF). Triptolide and its derivatives (Omtriptolide, Minnelide, (5R)-5-hydroxytriptolide) have been proven to have a variety of pharmacological effects. This study comprehensively reviewed the antifibrotic mechanism of TPL and its derivatives, and discussed the application of advanced nanoparticles (NPs) drug delivery system in the treatment of fibrotic diseases by TPL. The results show that TPL can inhibit immune inflammatory response, relieve oxidative stress and endoplasmic reticulum stress (ERS), regulate collagen deposition and inhibit myofibroblast production to play an anti-fibrosis effect and reduce organ injury. A low dose of TPL has no obvious toxicity. Under pathological conditions, a toxic dose of TPL has a protective effect on organs. The emergence of TPL derivatives (especially Minnelide) and NPs drug delivery systems promotes the anti-fibrosis effect of TPL and reduces its toxicity, which may be the main direction of anti-fibrosis research in the future.


Sujet(s)
Diterpènes , Composés époxy , Fibrose , Phénanthrènes , Diterpènes/pharmacologie , Diterpènes/composition chimique , Diterpènes/administration et posologie , Phénanthrènes/pharmacologie , Phénanthrènes/composition chimique , Phénanthrènes/administration et posologie , Composés époxy/pharmacologie , Composés époxy/composition chimique , Composés époxy/administration et posologie , Humains , Fibrose/traitement médicamenteux , Animaux , Antifibrotiques/pharmacologie , Antifibrotiques/composition chimique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE